Get the Stockscreener App
56.57
0.39%
-0.22
After Hours:
56.71
0.14
+0.25%
Overview
News
Price History
Option Chain
Financials
Why BMY Down?
Discussions
Forecast
Stock Split
Dividend History
Bristol Myers Squibb Co stock is traded at $56.57, with a volume of 8.63M.
It is down -0.39% in the last 24 hours and down -3.61% over the past month.
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
See More
Previous Close:
$56.79
Open:
$56.34
24h Volume:
8.63M
Relative Volume:
0.85
Market Cap:
$114.73B
Revenue:
$47.44B
Net Income/Loss:
$-7.26B
P/E Ratio:
-15.76
EPS:
-3.59
Net Cash Flow:
$13.80B
1W Performance:
-1.92%
1M Performance:
-3.61%
6M Performance:
+41.21%
1Y Performance:
+8.16%
1-Day Range:
$56.31
$56.80
1-Week Range:
$55.93
$57.60
52-Week Range:
$39.35
$61.08
Bristol Myers Squibb Co Stock (BMY) Company Profile
Name
Bristol Myers Squibb Co
Sector
Industry
Phone
(609) 252-4621
Address
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
56.57 | 114.73B | 47.44B | -7.26B | 13.80B | -3.59 |
|
LLY
Lilly Eli Co
|
781.98 | 703.25B | 40.86B | 8.37B | -2.28B | 9.25 |
|
NVO
Novo Nordisk Adr
|
87.65 | 389.28B | 39.36B | 13.79B | 9.83B | 3.086 |
|
JNJ
Johnson Johnson
|
144.19 | 347.16B | 87.70B | 14.68B | 19.03B | 6.05 |
|
ABBV
Abbvie Inc
|
181.22 | 320.24B | 55.53B | 5.12B | 15.62B | 2.88 |
|
MRK
Merck Co Inc
|
99.14 | 250.79B | 63.17B | 12.15B | 14.84B | 4.77 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-16-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Nov-12-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-25-24 | Downgrade | Citigroup | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jul-29-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-11-24 | Downgrade | Societe Generale | Buy → Hold |
| Feb-06-24 | Downgrade | Redburn Atlantic | Buy → Neutral |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-15-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-27-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Oct-27-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Oct-27-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jul-10-23 | Initiated | SVB Securities | Market Perform |
| Jun-28-23 | Initiated | Daiwa Securities | Outperform |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Jan-17-23 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-18-22 | Initiated | Credit Suisse | Neutral |
| Oct-10-22 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-14-22 | Downgrade | Berenberg | Buy → Hold |
| Jun-03-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Underweight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Nov-01-21 | Downgrade | Argus | Buy → Hold |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-30-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-13-21 | Upgrade | Truist | Hold → Buy |
| Nov-16-20 | Upgrade | Societe Generale | Hold → Buy |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Nov-06-20 | Downgrade | Gabelli & Co | Buy → Hold |
| Oct-19-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Jul-28-20 | Initiated | Raymond James | Outperform |
| Apr-02-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-06-20 | Resumed | Citigroup | Buy |
| Dec-13-19 | Upgrade | Argus | Hold → Buy |
| Nov-22-19 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Aug-14-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| May-28-19 | Initiated | Goldman | Buy |
| May-20-19 | Downgrade | Argus | Buy → Hold |
| May-03-19 | Upgrade | Barclays | Equal Weight → Overweight |
| May-03-19 | Resumed | JP Morgan | Overweight |
| Jan-15-19 | Upgrade | Societe Generale | Sell → Buy |
| Oct-22-18 | Downgrade | Citigroup | Buy → Neutral |
View All
Bristol Myers Squibb Co Stock (BMY) Latest News
3 High-Yield Dividend Stocks to Buy Now and Hold at Least a Decade - The Motley Fool
Bristol Myers Squibb (BMY) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance
Bristol Myers Squibb Co. stock rises Friday, still underperforms market - MarketWatch
Bristol Myers Squibb to Present at J.P. Morgan’s 43rd Annual Healthcare Conference - BioSpace
Bristol Myers Squibb call volume above normal and directionally bullish - TipRanks
FDA approves drugs from Vertex, Novo, Bristol Myers to wrap 2024 - BioPharma Dive
Pfizer, BMS and more ring in 2025 with fresh round of drug price increases: report - FiercePharma
Ex-Dividend Reminder: Bristol Myers Squibb, Globe Life and American Express - Nasdaq
2024 Ends With Greenlights for Merck’s PAH Drug in UK and BMS’ Opdivo Injection in US - BioSpace
Bristol Myers celebrates 10 years of Opdivo with FDA approval for subcutaneous version - FiercePharma
Bristol-Myers Squibb's (NYSE:BMY) investors will be pleased with their 2.4% return over the last five years - Yahoo Finance
Profits slide at main Irish unit of drug giant Bristol Myers Squibb - The Irish Times
Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Is Bristol-Myers Squibb Company (BMY) Among the Best Pharma Dividend Stocks to Buy In 2024? - Insider Monkey
2025 drug price rise: Pharma companies plan to make more than 250 medicines more expensive - Fast Company
Pre-tax profits down 42% at Irish arm of Bristol Myers Squibb - RTÉ News
Is Trending Stock Bristol Myers Squibb Company (BMY) a Buy Now? - Yahoo Finance
FDA approves injectable version of Bristol Myers Squibb's cancer drug Opdivo - MSN
Oncology Pharmaceuticals Market Research 2024-2029, - GlobeNewswire
Bristol-Myers Squibb (NYSE:BMY) Share Price Passes Above Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Bristol-Myers Squibb's SWOT analysis: navigating challenges in biopharma stock - Investing.com
13 Best Pharma Dividend Stocks To Buy In 2024 - Insider Monkey
Is Bristol-Myers Squibb Co. (BMY) the Best Stock for 10 Years? - Insider Monkey
Bristol-Myers Squibb Stock: Clearly Undervalued, Excellent 2H24 Culminates In Opdivo 'Subcu' Approval - Seeking Alpha
FDA Approves BMS’ Opdivo Qvantig with Halozyme’s ENHANZE Technology - Contract Pharma
Bristol-Myers Squibb’s Patent Expansion Plan May Run into Regulator Trouble - TipRanks
Bristol Myers Squibb patents IKZF1-4 degradation inducers - BioWorld Online
FDA approves BMS’ Opdivo Qvantig for solid tumour indications - Yahoo Finance
Halozyme Announces FDA Approval of Bristol Myers Squibb's Opdivo Qvantig™ with ENHANZE® for Subcutaneous Use in Most Previously Approved Adult Solid Tumor Opdivo® (nivolumab) Indications - PR Newswire
Bristol Myers: Opdivo Qvantig approved for subcutaneous use - Marketscreener.com
Bristol-Myers Squibb (NYSE:BMY) Is Paying Out A Larger Dividend Than Last Year - Yahoo Finance
Injectable version of Bristol Myers Squibb cancer drug Opdivo gets USFDA okay - Medical Dialogues
Bristol Myers Squibb Receives FDA Approval for Cancer Treatment - Marketscreener.com
Bristol Myers Squibb (BMY) Stock Moves -0.55%: What You Should Know - Yahoo Finance
U.S. Food and Drug Administration Approves Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo® (nivolumab) Indications1,2Bristol Myers Squibb - Bristol Myers Squibb - News
US FDA Approves Subcutaneous Opdivo, Extending Key BMS Franchise Into 2030s - Scrip
BMS secures subcutaneous Opdivo approval - FirstWord Pharma
FDA Approves Injection Version of OpdivoEnhancing Cancer TreatmentNews and Statistics - IndexBox, Inc.
FDA Approval of Injectable Opdivo: Bristol Myers Squibb Fights Off Patent Cliff Concerns - Yahoo Finance
US FDA approves injectable form of Bristol Myers' Opdivo By Reuters - Investing.com
BMYBristol-Myers Squibb Co. Latest Stock News & Market Updates - StockTitan
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MarketWatch
Is Bristol Myers Squibb (BMY) Stock Undervalued Right Now? - Yahoo Finance
Bristol-Myers Climbs After Jefferies Upgrades Stock On Schizophrenia Drug’s $10B Potential: Retail Is Excited - MSN
Bristol Myers Squibb Co. stock rises Tuesday, still underperforms market - MarketWatch
The Bristol Myers Squibb Foundation - Bristol Myers Squibb
Bristol Myers Squibb Co. stock rises Monday, still underperforms market - MarketWatch
BMS sees success in Phase III Sotyktu psoriatic arthritis trials - Yahoo Finance
Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer - BioSpace
Bristol Myers wins US FDA approval for new type of schizophrenia drug - AOL
Bristol Myers announces positive Phase 3 results for arthritis drug - Investing.com
Bristol Myers Squibb Co Stock (BMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.08%
0.75%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):